---
title: "Gastric Cancer Treatment Decisions"
editor: visual
bibliography: zotero.bib
---

# Chemo vs ChemoRT preop

Immunotherapy for MSI-Hi gastric cancer [@raimondi2839]

| Study         | Rx                                                       |
|---------------|----------------------------------------------------------|
| Keynote 059   | Pembro for advanced previous Rx gastric                  |
| Keynote 061   | Advanced GC progressed Pembro vs Taxol                   |
| Keynote 062   | Advanced previous rx HER2neg Pembro vs chemo             |
| Kenote 016    | dMMR CRC and pMMR Pembro. 0% response in pMMR            |
| Checkmate 649 | Advanced GC/GEJ: Nivo + chemo. Response in 55% of MSI-Hi |
|               |                                                          |

# ctDNA

ctDNA from CRITICS trial: Leal Nature Communications2020 Jan 27 11(1)

ctDNA in locally advanced gastric cancer Wo JY, Clin Cancer Res 2021 27(23)

baseline ctDNA mutational load correlates with response to Pembro KIM ST Nat Med 2018 Sep 24(9)

GALAXY trial: Only ctDNA positive patients benefit from adjuvant chemo
